In recent research on reproduction, new treatment options for solid cancer tumors such as breast cancer, lung cancer, and melanoma have emerged. This work has been influenced by the late University of Virginia School of Medicine scientist, John Herr, who collaborated with Craig L. Slingluff Jr., MD of the UVA Cancer Center before his sudden death in 2016. Their investigation focused on the potential of a discovery from Herr’s lab to be utilized in cancer treatment.Herr’s research into the SAS1B protein has shown promising results after years of research. According to a new scientific paper in the Journal for ImmunoTherapy of Cancer, the findings could potentially lead to new and impactful treatments for various types of cancer, many of which are notoriously difficult to treat. Slingluff, a senior author on the paper and a surgical oncologist and translational immunologist at UVA Health and the UVA School of Medicine, expressed excitement about the potential of SAS1B as a valuable new target for human cancers. He also mentioned that the findings further support the hope of making a significant difference in cancer treatment.
Promising New Cancer Target
Dr. Herr’s team’s work, along with subsequent collaborative research, has been acknowledged by the journal, with John being included as a senior author. Dr. Herr, originally focused on contraceptive and reproductive health research, developed the first home fertility test for men, known as SpermCheck, which is widely available in pharmacies. His findings on the SAS1B protein found in developing eggs in women could have significant implications for cancer research.
revolutionize cancer treatment by allowing for more precise and effective immunotherapies,” said Slingluff. “This approach could greatly reduce the side effects associated with traditional cancer treatments, as well as improve overall patient outcomes.”
With their findings, the researchers hope to pave the way for new cancer immunotherapies. This could lead to more targeted and less toxic treatments for cancer patients, ultimately improving their quality of life. Additionally, this research opens up the possibility of developing novel antibody-based immunotherapies that specifically target cancer cells while leaving healthy cells unharmed. This could mark a significant advancement in the field of cancer treatment.The research conducted by Slingluff and his team indicates that the treatment of various types of cancer could see significant improvements and a decrease in mortality rates. The findings show promise, although there is still more work to be done. If successful, this approach could be a major advancement in cancer treatment. Slingluff points out that solid-organ cancers are particularly challenging to treat, and patients often have limited options for treatment. He also mentions that immune therapy has been transforming the treatment of cancer, but certain types of cancer have been resistant to this approach due to the absence of suitable targets.
There are hopes that the work started by John Herr will bring new hope to patients with resistant cancers.
The UVA Cancer Center is dedicated to finding new ways to improve cancer care and has been honored with a “comprehensive” designation from the National Cancer Institute. This designation is only given to elite cancer centers with exceptional cancer care and research programs.
The upcoming Paul and Diane Manning Institute of Biotechnology at Fontaine Research Park is also focused on advancing the field of immunotherapy.The goal is to speed up the creation of new medical treatments and cures for a wide range of diseases, which will ultimately change the way healthcare is provided in Virginia and beyond.
Â
